RUS will require Primary Recipients to evaluate each action taken with an Ultimate Recipient to ensure consistency with the terms of the executed program alternative. Primary Recipients will be responsible for documenting activities that fall below the established threshold. RUS will review the Primary Recipient’s documentation of actions that fall below the threshold prior to providing reimbursement with Federal funds.

Any EE Program activity for which exemptions and standard treatments are not applicable would be subject to Section 106 review under procedures established by the PA or other program alternative. Therefore, the program alternative must define a clear threshold for RUS involvement in Section 106 review.

Although few in number, the comments on the Conceptual Outline received thus far have been supportive of the development of a nationwide PA, the need for streamlining, especially given the large number of reviews expected to be generated by EE Program activities, and the approach reflected in the Conceptual Outline. Based on these comments, RUS is proceeding with development of the first draft of the nationwide PA. The program alternative will be executed prior to RUS issuing a finding of no significant impact (FONSI). Both the FONSI and findings of no significant impact will be executed prior to RUS issuing a development of the first draft of the nationwide PA. The program alternative will be executed prior to RUS issuing a finding of no significant impact (FONSI). Both the FONSI and documents related to the program alternative will be made available to the public on RUS’s Web site at http://www.rurdev.usda.gov/UWP-ea.htm.


Nivin Elgohary,
Assistant Administrator, Electric Programs, USDA, Rural Utilities Service.

[FR Doc. 2013–02393 Filed 2–5–13; 8:45 am]
BILLING CODE P

DEPARTMENT OF TRANSPORTATION
Federal Aviation Administration

14 CFR Part 39
RIN 2120–AA64

Airworthiness Directives; GROB–WERKE Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Proposed rule; correction.

SUMMARY: The FAA is correcting a Notice of Proposed Rulemaking (NPRM) that published in the Federal Register.

That NPRM applies to all GROB–WERKE Model G115EG airplanes. The docket number in the preamble and in the section titled PART 39—AIRWORTHINESS DIRECTIVES, paragraph 2, is incorrect. This document corrects that error. In all other respects, the original document remains the same.

DATES: The last date for submitting comments to the NPRM (78 FR 2910, January 15, 2013) remains March 1, 2013.

ADDRESSES: You may examine the AD docket on the Internet at http://www.regulations.gov; or in person at the Docket Management Facility between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this AD, the regulatory evaluation, any comments received, and other information. The address for the Docket Office (phone: 800–647–5527) is Document Management Facility, U.S. Department of Transportation, Docket Operations, M–30, West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue SE., Washington, DC 20590.

FOR FURTHER INFORMATION CONTACT: Taylor Martin, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329–4138; fax: (816) 329–4090; email: taylor.martin@faa.gov.


As published, the docket number in the preamble and in the section titled PART 39—AIRWORTHINESS DIRECTIVES, paragraph 2, is incorrect. No other part of the preamble or regulatory information has been changed; therefore, only the changed portion of the NPRM is being published in the Federal Register.

The last date for submitting comments to the NPRM remains March 1, 2013.

Correction of Non-Regulatory Text

§ 39.13 [Corrected]

In the Federal Register of January 15, 2013, on page 2911, in the 3rd column, on line 20, in paragraph (2) under PART 39—AIRWORTHINESS DIRECTIVES of Directorate Identifier 2012–CE–046–AD is corrected to read as follows:

* * * * * "FAA–2013–0013;"
* * * * *

Issued in Kansas City, Missouri, on January 28, 2013.

Earl Lawrence,
Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. 2013–02578 Filed 2–5–13; 8:45 am]
BILLING CODE 4910–13–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 201, 314, and 601
[Docket No. FDA–2013–N–0059]

Center for Drug Evaluation and Research; Prescription Drug Labeling Improvement and Enhancement Initiative; Request for Comments and Information

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification of an initiative; request for comments and information.

SUMMARY: The Food and Drug Administration (FDA) is announcing the establishment of a docket to receive comments on the proposed implementation of FDA’s Prescription Drug Labeling Improvement and Enhancement Initiative and on a proposed pilot project relating to the voluntary conversion of labeling to the “Physician Labeling Rule (PLR)” format described in the 2006 FDA final rule, “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products.” The purpose of the initiative and the pilot project is to enhance the safe and effective use of prescription drugs by facilitating optimal communication through labeling. FDA is seeking public comment on this initiative, and the pilot project, particularly from stakeholders who develop and use prescription drug labeling. Comments received from stakeholders will assist the Agency in identifying and addressing feasibility and implementation issues associated with this initiative.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 201, 314, and 601
[Docket No. FDA–2013–N–0059]

Center for Drug Evaluation and Research; Prescription Drug Labeling Improvement and Enhancement Initiative; Request for Comments and Information

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification of an initiative; request for comments and information.

SUMMARY: The Food and Drug Administration (FDA) is announcing the establishment of a docket to receive comments on the proposed implementation of FDA’s Prescription Drug Labeling Improvement and Enhancement Initiative and on a proposed pilot project relating to the voluntary conversion of labeling to the “Physician Labeling Rule (PLR)” format described in the 2006 FDA final rule, “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products.” The purpose of the initiative and the pilot project is to enhance the safe and effective use of prescription drugs by facilitating optimal communication through labeling. FDA is seeking public comment on this initiative, and the pilot project, particularly from stakeholders who develop and use prescription drug labeling. Comments received from stakeholders will assist the Agency in identifying and addressing feasibility and implementation issues associated with this initiative.